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Tamoxifen remains an important adjuvant therapy to reduce the rate of breast cancer recurrence among patients with oestrogen-
receptor-positive tumours. Cytochrome P-450 2D6 metabolises tamoxifen to metabolites that more readily bind the oestrogen
receptor. This enzyme also metabolises selective serotonin reuptake inhibitors (SSRI), so these widely used drugs – when taken
concurrently – may reduce tamoxifen’s prevention of breast cancer recurrence. We studied citalopram use in 184 cases of breast
cancer recurrence and 184 matched controls without recurrence after equivalent follow-up. Cases and controls were nested in a
population of female residents of Northern Denmark with stages I–III oestrogen-receptor-positive breast cancer 1985–2001 and
who took tamoxifen for 1, 2, or most often for 5 years. We ascertained prescription histories by linking participants’ central personal
registry numbers to prescription databases from the National Health Service. Seventeen cases (9%) and 21 controls (11%) received
at least one prescription for the SSRI citalopram while taking tamoxifen (adjusted conditional odds ratio¼0.85, 95% confidence
interval¼0.42, 1.7). We also observed no reduction of tamoxifen effectiveness among regular citalopram users (X30% overlap with
tamoxifen use). These results suggest that concurrent use of citalopram does not reduce tamoxifen’s prevention of breast cancer
recurrence.
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Tamoxifen is a selective oestrogen receptor modulator (Jordan
and Dowse, 1976) that reduces by half the risk of breast cancer
recurrence in early-stage patients whose tumour cells express the
oestrogen receptor (Early Breast Cancer Trialists’ Collaborative
Group, 2005). To be pharmacologically active, tamoxifen must be
metabolised to secondary metabolites that bind the oestrogen
receptor 100-fold more readily than tamoxifen itself (Malet et al,
1988). Four cytochrome P-450 enzymes (CYPs) catalyse this
activation (CYP2D6, CYP3A4, CYP3A5, and CYP2C9) (Malet et al,
1988). CYP2D6 catalyses formation of 4-hydroxytamoxifen from
tamoxifen (Coller et al, 2002) and formation of 4-hydroxy-N-
desmethyltamoxifen from N-desmethyltamoxifen (Stearns et al,
2003). These two secondary metabolites have the highest binding
affinity for the oestrogen receptor, and binding affinity correlates
with inhibition of cell growth (Coezy et al, 1982). The secondary
metabolites are, therefore, the most important modulators of the
oestrogen receptor in the tamoxifen pathway (Lim et al, 2005).
Breast cancer patients treated with tamoxifen may also take
other prescription medications that are metabolised by some of the
same enzymes that activate tamoxifen. For example, depression is
a common comorbidity in breast cancer patients (Massie, 2004),
and many selective serotonin reuptake inhibitors (SSRI), which are
widely used medications indicated primarily to treat depression
(Hansen et al, 2003), are metabolised by CYP2D6 (Zanger et al,
2004). SSRI competition with tamoxifen and N-desmethyltamo-
xifen for CYP2D6, or direct inhibition of CYP2D6 by SSRI, could
reduce the production of the tamoxifen metabolites with high
receptor-binding affinity, and thereby reduce tamoxifen’s preven-
tion of breast cancer recurrence. Competition between tamoxifen
and the SSRI paroxetine reduced the plasma concentration of
endoxifen in a cross-over clinical trial (Stearns et al, 2003).
Furthermore, the mean plasma concentration of 4-hydroxy-N-
desmethyltamoxifen was more than two-fold greater among
women who were taking no CYP2D6 competitor drug than among
women who were taking such a drug (Jin et al, 2005). In vivo
studies thus demonstrate a compelling biological basis for the
hypothesis that concomitant use of SSRI would reduce tamoxifen’s
prevention of breast cancer recurrence.
In the largest study to date of the potential for drug–drug
interaction to reduce tamoxifen’s protection against breast cancer
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srecurrence, we examined whether Danish breast cancer patients
with oestrogen-receptor-positive tumours who were treated with
tamoxifen for 1, 2, or most often for 5 years had a higher rate of
recurrence if they were concomitantly taking the SSRI citalopram
or its S-stereoisomer (‘citalopram’ from here onwards) than if they
were not. As described in more detail below, citalopram was the
most frequently prescribed SSRI in the study population.
MATERIALS AND METHODS
The study was approved by the Boston University Medical Campus
Institutional Review Board and The Regional Committee on
Biomedical Research Ethics of Aarhus County.
Study population
The source population included female residents of four Northern
Danish counties (Aarhus, North Jutland, Viborg, and Ringkøbing)
aged 35–69 at diagnosis of primary International Union Against
Cancer stage I, II, or III breast cancer (UICC, 1997) between 1985
and 2001 and who were reported to the Danish Breast Cancer
Cooperative Group (DBCG). The DBCG has enrolled nearly all
Danish breast cancer patients younger than age 70 at diagnosis
into its clinical database since 1977 (Andersen and Mouridsen,
1988; Jensen et al, 2003). More than 90% of Danish breast cancer
cases are reported to the DBCG and more than half of the DBCG
patients are enrolled in clinical trials (Andersen and Mouridsen,
1988). The same standardized forms are used to follow all patients
reported to the DBCG, regardless of whether they enrol in a trial,
so the registry provides the data quality advantage of a clinical trial
setting with the generalisability advantage of a population-based
setting.
We divided the source population into three groups: (a) group I
women whose tumour expressed the oestrogen receptor protein
and who were treated with tamoxifen for at least 1 year; (b) group
II women whose tumour did not express the oestrogen receptor
protein, were not treated with tamoxifen, and who survived for at
least one year; and (c) group III women, comprising all others, who
were excluded from this analysis. Group I women were assigned to
tamoxifen therapy protocols of 1, 2, or 5 years, depending on the
guideline extant in Denmark at the time of their diagnoses. We
included group II women to estimate the direct association of
citalopram prescription with recurrence rate, if any. We further
restricted the source population to women diagnosed with breast
cancer after the date that their county of residence began to
maintain an electronic prescription database (Aarhus¼1996,
North Jutland¼1989, Ringkøbing¼1998, Viborg¼1998), which
were used to ascertain use of prescription medications, including
citalopram. Follow-up time began 1 year after the date of breast
cancer diagnosis and continued until the date of the first of breast
cancer recurrence, death from any cause, loss to follow-up (e.g.,
emigration), 10 years of follow-up, or 1 September 2006.
Cases were women with local or distant breast cancer recurrence
occurring during their follow-up time among the members of
groups I and II. We selected one control for each case without
replacement from members of the source population who had not
had a breast cancer recurrence after the same amount of follow-up
time. We matched controls to cases on (a) group membership
(group I or II), (b) menopausal status at diagnosis (premenopausal
or postmenopausal), (c) date of breast cancer surgery (caliper
matched±12 months), (d) county of residence at the time of
diagnosis, and (e) UICC stage at diagnosis (stage I, II, or III).
Data collection
We used the Danish Civil Personal Registration (CPR) number
assigned to each case and control to link data sets. The CPR is a
unique identification number assigned to all Danish residents alive
on 1 April 1968, born thereafter, or upon immigration.
We collected demographic information (age, menopausal status,
and hospital of diagnosis), tumour characteristics (UICC stage,
histological grade, and oestrogen-receptor expression), and
therapy characteristics (primary surgical tumour management,
receipt of radiation therapy, receipt of chemotherapy, and receipt
of tamoxifen therapy) from the DBCG database.
We collected data on receipt of citalopram prescription and
other potential CYP2D6 inhibitors (including other SSRI) by
linking the CPR number of cases and controls to the prescription
databases maintained by each county (see, for example, the
description of North Jutland’s database (Gaist et al, 1997)).
Analytic variables
Recurrence We used the DBCG definition of breast cancer
recurrence as any type of breast cancer subsequent to the initial
course of therapy (Andersen and Mouridsen, 1988). Given the
definition of the source population and follow-up time, all cases of
recurrence occurred between 1 and 10 years after the primary
breast cancer diagnosis.
Prescription status Prescription medications are coded by the
Anatomical Therapeutic Chemical (ATC) classification system
(WHO Collaborating Centre for Drug Statistics Methodology,
2007). We defined SSRI antidepressants as all those classified in
group N06AB by the ATC. These are the SSRI drugs: zimeldine
(N06AB02), fluoxetine (N06AB03), citalopram (N06AB04), parox-
etine (N06AB05), sertraline (N06AB06), alaproclate (N06AB07),
fluvoxamine (N06AB08), etoperidone (N06AB09), and escitalo-
pram (N06AB10). We defined citalopram exposure as any
prescription for citalopram (N06AB04) or its S-stereoisomer
escitalopram (N06AB10).
We classified cases and controls as those with no record of a
citalopram prescription during their follow-up time (never
citalopram) and those with any record of prescription for
citalopram during their follow-up time (ever citalopram). We
used a similar procedure to classify cases and controls as ever or
never users of another SSRI or of another prescription medication
that is a CYP2D6 inhibitor or substrate, aside from those indicated
to treat breast cancer recurrence or its effects. See the Supple-
mentary online material for a complete list of these medications
and the frequency of their use in the study population.
For group I women who ever had a citalopram prescription, we
calculated the percentage of time on tamoxifen when they were
simultaneously taking citalopram. We created categories of (a)
intermittent citalopram use, defined as citalopram use overlapping
tamoxifen use for more than 0% but less than 30% of the time on
tamoxifen and (b) regular citalopram use, defined as citalopram
use overlapping tamoxifen use for 30% or more of the time on
tamoxifen. We chose 30% as the overlap boundary to allow
sufficient sample size in the regular citalopram subgroup, while
also investigating a substantial period of SSRI and tamoxifen
comedication.
Covariates We defined the following set of covariates: (a) time
period of breast cancer diagnosis (1985–1993, 1994–1996, and
1997–2001), (b) age at diagnosis (35–44 years, 45–54 years,
55–64 years, and 65–70 years), (c) menopausal status at diagnosis
(premenopausal and postmenopausal), (d) county of residence
at diagnosis (Aarhus, North Jutland, Viborg, and Ringkøbing),
(e) UICC stage at diagnosis (stages I, II, and III), histological grade
(grade I, II, III, and missing), surgery type (breast conserving
surgery and mastectomy), and receipt of systemic adjuvant
chemotherapy (yes and no), and (f) receipt of a prescription for
another medication that is a CYP2D6 inhibitor or substrate,
including other SSRI, while taking tamoxifen.
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All analyses were conducted within strata of the two groups
(oestrogen-receptor positive and treated with tamoxifen or
oestrogen-receptor negative and not treated with tamoxifen). We
computed the frequency and proportion of cases and controls
within categories of assigned protocol of tamoxifen duration, of
citalopram use, of use of other CYP2D6 inhibitors or substrates,
and of the covariates. We calculated the number of cases and
controls ever receiving citalopram, the number of total prescrip-
tions for citalopram summed over all cases or controls, and the
range of the number of prescriptions for citalopram received by
each individual case or control.
We estimated the rate ratio associating citalopram prescription
with breast cancer recurrence as the odds ratio (OR) in a
conditional logistic regression including only citalopram use as
the exposure variable and conditioned on the matched factors. By
design, this ratio adjusts for confounding by the matched factors
(Greenland, 2008). We examined whether the effect of citalopram
use was modified by duration of tamoxifen therapy in a stratified
analysis. Finally, we adjusted for residual confounding by the
covariates that were not included in the matching by including
them as independent variables in the conditional logistic regres-
sion. We retained in the final model any covariate that affected the
log OR from the conditional logistic regression model associating
citalopram use with breast cancer recurrence rate by more than
10% (Greenland, 1989). All estimates are accompanied by a 95%
confidence interval (CI) calculated by the profile likelihood
method. All analyses were performed using SAS version 9.
RESULTS
Table 1 shows the frequency and proportion of cases and controls,
within strata of group, in the categories of the covariates. About
two-thirds of cases and controls in both groups were diagnosed
with primary breast cancer during the period 1997–2001, and the
majority was resident in Aarhus or North Jutland counties,
because the prescription registries began first in these two
counties. A large majority had mastectomy as their primary
surgical intervention, which is consistent with the clinical practice
pattern previously reported in this region during this time period
(Ahern et al, 2008). Group I women (positive oestrogen-receptor
expression and treated with tamoxifen) were more likely to be
post-menopausal (87%) than were group II women (66%; negative
oestrogen-receptor expression and not treated with tamoxifen).
Group I women were also less likely to receive systemic adjuvant
chemotherapy (11 and 13% of cases and controls, respectively)
than were group II women (80 and 70% of cases and controls,
respectively); reflecting the preference for hormonal therapy
over systemic adjuvant chemotherapy in women whose tumours
expressed the oestrogen receptor. Between 3 and 11% of cases and
controls ever used citalopram while taking tamoxifen (group I)
or during their follow-up period (group II).
Table 2 depicts the pattern of SSRI prescriptions received by
cases and controls. In both groups, SSRI prescriptions were
primarily written for citalopram or its S-stereoisomer, escitalo-
pram. For example, 17 of 23 group I cases (74%) ever prescribed
an SSRI had at least one prescription for citalopram, accounting
for 86% of the total number of prescriptions. Similarly, 22 of 30
group I controls (73%) ever prescribed an SSRI had at least one
prescription for citalopram, accounting for 64% of their prescrip-
tions. Sertraline accounted for the majority of the remaining
prescriptions (11% of the total for cases and 23% for controls).
Group I women who ever used citalopram while taking
tamoxifen did not have a higher rate of breast cancer recurrence
than women who never used citalopram while taking tamoxifen
(Table 3; OR¼0.79, 95% CI¼0.40, 1.6). This OR was not
substantially modified by duration of tamoxifen therapy
Table 1 Frequency and proportion of cases of breast cancer recurrence
and matched controls within group strata (I) expressing the oestrogen
receptor and receiving at least 1 year of tamoxifen therapy (ERP+/TAM+),
or (II) not expressing the oestrogen receptor, never receiving tamoxifen
therapy, and surviving at least 1 year after diagnosis (ERP /TAM )
Group I: ERP+/
TAM+ (n (%))
Group II: ERP /
TAM  (n (%))
Cases Controls Cases Controls
Citalopram prescription
Ever 17 (9) 21 (11) 3 (3) 5 (6)
Never 167 (91) 163 (89) 84 (97) 82 (94)
Other CYP2D6 inhibitors, including other SSRI
Ever 48 (26) 51 (28) 25 (29) 17 (20)
Never 136 (74) 133 (72) 62 (71) 70 (80)
Diagnosis year
a
1985–1993 33 (18) 34 (18) 13 (15) 11 (13)
1994–1996 32 (17) 29 (16) 17 (20) 18 (21)
1997–2001 119 (65) 121 (66) 57 (66) 58 (67)
Age at diagnosis
35–44 13 (7) 11 (6) 15 (17) 12 (14)
45–55 38 (21) 34 (18) 37 (43) 29 (33)
55–65 91 (49) 93 (51) 26 (30) 29 (33)
65–70 42 (23) 46 (25) 9 (10) 17 (20)
Menopausal status at diagnosis
a
Premenopausal 24 (13) 24 (13) 30 (34) 30 (34)
Postmenopausal 160 (87) 160 (87) 57 (66) 57 (66)
County of residence at diagnosis
a
Aarhus 70 (38) 70 (38) 37 (43) 37 (43)
North Jutland 88 (48) 88 (48) 37 (43) 37 (43)
Viborg 15 (8) 15 (8) 9 (10) 9 (10)
Ringkøbing 11 (6) 11 (6) 4 (5) 4 (5)
UICC tumour stage at diagnosis
a
Stage I 7 (4) 7 (4) 4 (5) 4 (5)
Stage II 79 (43) 79 (43) 41 (47) 41 (47)
Stage III 98 (53) 98 (53) 42 (48) 42 (48)
Histological grade
Grade I 31 (17) 33 (18) 4 (5) 17 (20)
Grade II 73 (40) 87 (47) 29 (33) 2 (2)
Grade III 44 (24) 24 (13) 38 (44) 22 (25)
Missing 36 (20) 40 (22) 16 (18) 46 (53)
Surgery type
Breast conserving
surgery
22 (12) 22 (12) 9 (10) 4 (5)
Mastectomy 162 (88) 162 (88) 78 (90) 83 (95)
Radiation therapy
Yes 86 (47) 79 (43) 43 (49) 36 (41)
No 98 (53) 105 (57) 44 (51) 51 (59)
Tamoxifen protocol
1 year 57 (31) 57 (31) Not
applicable
Not
applicable
2 years 10 (5.4) 10 (5.4)
5 years 117 (64) 117 (64)
Systemic adjuvant chemotherapy
Yes 21 (11) 24 (13) 70 (80) 61 (70)
No 163 (89) 160 (87) 17 (20) 26 (30)
aVariable included in risk set sampling to match controls to cases.
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mately null effect persisted with adjustment for age category and
ever/never use of another CYP2D6 inhibitor or SSRI (OR¼0.85,
95% CI 0.42, 1.7). The effects were likewise approximately null
within cumulative citalopram prescription categories (intermittent
use OR¼0.72, 95% CI 0.30, 1.7; regular use OR¼1.1, 95% CI 0.37,
3.3). Citalopram use also had no substantial effect on recurrence in
group II women (adjusted OR¼0.78, 95% CI 0.17, 3.6), suggesting
that citalopram does not directly affect the risk of breast cancer
recurrence.
DISCUSSION
The results of this study do not support the hypothesis that
citalopram, taken concurrently with tamoxifen, reduces tamoxi-
fen’s protective effect against breast cancer recurrence in early-
stage patients whose tumour cells express the oestrogen receptor.
Our results extend the findings from an earlier study of 28 stage
II and III breast cancer patients with recurrence and their matched
controls at a single United States oncology centre, which also
reported no substantial modification of tamoxifen effectiveness by
concomitant use of SSRI inhibitors of CYP2D6 (Lehmann et al,
2004). These results may seem at odds with the strong biological
rationale and in vivo evidence that support the hypothesis that
CYP2D6 inhibition would reduce tamoxifen’s prevention of breast
cancer recurrence. It is possible, however, that SSRI medications
could reduce the plasma concentration of tamoxifen’s secondary
metabolites without reducing its anti-tumorigenicity (Ponzone
et al, 2004; Ratliff et al, 2004; Stearns et al, 2004). Tamoxifen doses
as much as 20-fold lower than the typical US dose of 20mgday
 1
affect biomarkers of cardiovascular, bone, and tumour end points
(Decensi et al, 1998, 2003), so the approximately three-fold
reduction in the plasma concentration of tamoxifen’s secondary
metabolites associated with concomitant receipt of the SSRI
paroxetine (Jin et al, 2005) may have little consequence.
The key mechanistic question may be whether reduced concen-
trations of active tamoxifen metabolites result in substantially
reduced occupancy of the oestrogen receptor. Dowsett and Haynes
(2003) estimated that, in postmenopausal women on a daily dose of
20mg tamoxifen, tamoxifen and its metabolites occupy 9994 of
10000 oestrogen receptors. Replicating their calculation using the
plasma concentrations of tamoxifen and its metabolites in women
with no CYP2D6 variant allele (Jin et al, 2005), tamoxifen and its
metabolites would occupy 9999 of 10000 receptors in women not
taking any SSRI and 9997 of 10000 receptors in women taking the
strong CYP2D6-inhibiting SSRI paroxetine. Steady-state concentra-
tions of tamoxifen and its metabolites may be sufficient to manifest
fully tamoxifen’s antitumorigenic effect in postmenopausal women
regardless of whether CYP2D6 inhibition reduces the concentration
of some tamoxifen metabolites.
Nonetheless, our results should be considered with the following
limitations in mind. First, the majority of SSRI prescriptions in
our study were for citalopram or its S-stereoisomer, both
originally manufactured by Lundbeck, a company headquartered
in Denmark. Citalopram is a modest inhibitor of CYP2D6
compared with some other SSRI medications (Jeppesen et al,
1996). These more potent inhibitors may reduce tamoxifen’s
protection against breast cancer recurrence, but their interaction
with tamoxifen would not have been well measured by this study.
Table 2 Number of cases and controls receiving any prescription for each SSRI, and total number of prescriptions for each SSRI within group strata (I)
expressing the oestrogen receptor and receiving at least 1 year of tamoxifen therapy (ERP+/TAM+), or (II) not expressing the oestrogen receptor, never
receiving tamoxifen therapy, and surviving at least 1 year after diagnosis (ERP /TAM )
Group I: ERP+/TAM+ n (no. of prescriptions)
[range of no. per person]
Group II: ERP /TAM  n (no. of
prescriptions) [range of no. per person]
SSRI name (ATC code) Cases Controls Cases Control
Zimeldine (N06AB02) 0 0 0 0
Fluoxetine (N06AB03) 1 (4) [4–4] 4 (24) [1–13] 2 (12) [1–11] 0
Citalopram (N06AB04)
a 16 (251) [1–53] 21 (123) [1–24] 3 (4) [1–2] 5 (64) [1–43]
Paroxetine (N06AB05) 2 (6) [1–5] 1 (1) [1–1] 1 (2) [2–2] 3 (20) [5–9]
Sertraline (N06AB06) 3 (32) [3–24] 7 (45) [1–15] 1 (2) [2–2] 1 (12) [12–12]
Alaproclate (N06AB07) 0 0 0 0
Fluvoxamine (N06AB08) 0 0 0 0
Etoperidone (N06AB09) 0 0 0 0
Escitalopram (N06AB10)
a 1 (2) [2–2] 1 (3) [3–3] 0 0
aIn the analysis, we defined citalopram exposure as any prescription for citalopram (N06AB04) or its S-stereoisomer escitalopram (N06AB10).
Table 3 Association between SSRI prescription and breast cancer recurrence within strata of (a) Group I, women with tumours that expressed the
oestrogen receptor and who received at least 1 year of tamoxifen therapy (ERP+/TAM+) or (b) Group II, women with tumours that did not express the
oestrogen receptor, who never received tamoxifen therapy, and who survived at least 1 year after diagnosis (ERP /TAM )
Citalopram prescription Cases/controls Crude OR (95% CI) Adjusted OR (95% CI)
a
(a) Group I: ERP+/TAM+
Never user 167/163 1.0 (reference) 1.0 (reference)
Ever user 17/21 0.79 (0.40, 1.6) 0.85 (0.42, 1.7)
Intermittent use 10/14 0.69 (0.30,1.6) 0.72 (0.30, 1.7)
Regular use 7/7 0.97 (0.34, 2.8) 1.1 (0.37, 3.3)
(b) Group II: ERP /TAM 
Never user 84/82 1.0 (reference) 1.0 (reference)
Ever user 3/5 0.60 (0.14, 2.5) 0.78 (0.17, 3.6)
aAdjusted for age category and other CYP2D6-inhibiting medications (see the Supplementary online material for a complete list of these medications and the frequency of their
use in the study population).
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functional CYP2D6 variants (Hayhurst et al, 2001) that affect the
metabolism of tamoxifen (Jin et al, 2005). The combination of
genotype and receipt of CYP2D6-inhibiting medications has been
related to tamoxifen effectiveness in a previous study (Goetz et al,
2007). We do not, however, expect ever-receipt of citalopram while
taking tamoxifen to be related to CYP2D6 genotype, as this
genotype would be unknown to the patient and provider at the first
citalopram prescription. This study’s results therefore pertain to
the usual clinical setting. In addition, CYP2D6 genotype is unlikely
to cause citalopram prescription, or to share a common causal
ancestor, so CYP2D6 genotype does not satisfy the requisite
causal structure of a confounder (Greenland et al, 1999). It may
be possible that CYP2D6 genotype is related to adherence to
citalopram prescription or to long-term maintenance of the
prescription, resulting from differences in the occurrence of
adverse drug reactions in women with the different alleles. Such a
relation could confound the association between breast cancer
recurrence and duration of citalopram prescription while taking
tamoxifen. Some non-randomized studies suggest such a relation
between genotype and SSRI adherence (Rau et al, 2004; Zourkova ´
et al, 2007), whereas others suggest no such relation (Stedman
et al, 2002; Gerstenberg et al, 2003; Roberts et al, 2004; Hedenmalm
et al, 2006; Sugai et al, 2006; Suzuki et al, 2006). In the only
randomized trial, CYP2D6 genotype was not related to either the
occurrence of adverse events or to adherence to paroxetine
prescription (Murphy et al, 2003). Paroxetine is the most potent
CYP2D6 inhibitor of tamoxifen metabolism among the SSRI class
(Jin et al, 2005). If CYP2D6 genotype does not affect receipt or
adherence to SSRI prescription, then it cannot confound the
association we have reported.
Last, we do not know the indications for which citalopram was
prescribed to the study participants, although ordinarily it would
be prescribed primarily to treat depression. SSRI may also be
prescribed to treat hot flushes (Stearns, 2006), but such prescrip-
tions are rare in Danish breast cancer patients.
Weighing against these limitations are the strengths of the data
quality. This study relied upon the Danish Breast Cancer
Cooperative Group’s registry of breast cancer patients, which
provides clinical trial quality data in a population-wide setting in
the four Northern Danish Counties. For example, the positive
predictive value of breast cancer recurrence recorded by the DBCG
equaled 99.4% in a validation study (Hansen et al, 1997), showing
that there are few false-positive recurrences registered in the
DBCG. In addition, of 1888 local and distant recurrences identified
by medical record review among 4455 breast cancer patients
assigned to a DBCG protocol, 1813 (96%) were correctly registered
as recurrences in the DBCG database, 74 (3.9%) were identified as
breast cancer deaths, and only 1 (0.05%) was not identified as
either a recurrence or breast cancer death.
The prescription databases are generated by a computerised
pharmacy accounting system that sends data to the Danish
National Health Service, which refunds part of the costs associated
with prescribed drugs. Given the direct connection between receipt
of prescription medications and the pharmacy accounting system
of the Danish National Health Service, we expect the prescription
records to have excellent validity. The prescriptions from the four
counties are merged into a research database at Aarhus University.
In Denmark, antidepressants are available only at pharmacies and
the patient must have a prescription from a medical doctor.
Therefore, the county prescription databases are expected to have
high sensitivity and specificity for ascertainment of citalopram
prescriptions in the source population. Furthermore, because the
prescription records antecede the date of breast cancer recurrence,
they are a prospective data source presumably immune to
differential classification bias (Rothman et al, 2008).
Despite these advantages, the study yielded only 17 cases of
breast cancer recurrence among tamoxifen-treated women who
had used citalopram while taking tamoxifen. The study was
designed with 80% power to detect an OR of 1.6, and ultimately
had 90% power to detect an OR of 2.3.
The results presented herein are, nonetheless, important and
timely. A United States Food and Drug Administration advisory
committee recently recommended relabelling tamoxifen with
information on gene–drug and drug–drug interactions mediated
by CYP2D6 (American Cancer Society, 2007). Furthermore, the
current practice guidelines of the United States National Compre-
hensive Cancer Network note that some SSRI reduce the formation
of active tamoxifen metabolites, that citalopram and venlaflaxine
appear to have minimal impact on tamoxifen metabolism, and
that ‘the clinical impact of these observations is not known’
(National Comprehensive Cancer Network, 2008). Breast cancer
patients taking tamoxifen and their physicians may therefore be
concerned about SSRI comedication, even when antidepressants
are strongly indicated. Our results suggest that citalopram
prescription does not reduce tamoxifen’s prevention of breast
cancer recurrence.
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